Black Diamond Therapeutics elects three Class III directors, ratifies auditor at annual meeting
Black Diamond Therapeutics, Inc.
- David M. Epstein, Wendy L. Dixon, and Kapil Dhingra elected as Class III directors to serve until 2026.
- Epstein received 26.4M votes for, 84k withheld; Dixon 19.1M for, 7.3M withheld; Dhingra 20.0M for, 6.4M withheld.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 31.0M for, 22k against, 18k abstain.
- Meeting held virtually May 16, 2023; 31.1M shares represented out of 36.5M outstanding.